GT Biopharma, Inc.
Business
GT Biopharma is a clinical-stage biopharmaceutical company developing immuno-oncology therapeutics based on proprietary Tri-specific Killer Engager (TriKE®) and Dual Targeting TriKE® fusion protein platforms that activate natural killer cells to target cancer cells. The company's product pipeline includes GTB-3650 for relapsed/refractory AML and MDS (Phase 1 ongoing), GTB-5550 for B7-H3-positive solid tumors (IND cleared), GTB-7550 for autoimmune disorders, and the suspended first-generation candidate GTB-3550. The company operates as a fabless developer relying on third-party contract manufacturers and University of Minnesota research partnerships for preclinical and clinical advancement.
Summary from 10-K filed 2026-03-02
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenues | — | — | — | — | — | |
| Research and development | 3 | 6 | 6 | 9 | 10 | |
| Selling, general and administrative (including $432,000 and $230,000 of stock compensation during the years ended December 31, 2025 and 2024, respectively) | 9 | 9 | 7 | 12 | 48 | |
| Loss from Operations | −12 | −14 | −14 | −21 | −58 | |
| Interest income | 123,000 | 402,000 | 780,000 | −292,000 | −38,000 | |
| Interest expense | −127,000 | — | −213,000 | — | — | |
| Loss on initial recognition of Greenshoe Rights liability | −29 | — | — | — | — | |
| Change in fair value of Greenshoe Rights liability | 11 | — | — | — | — | |
| Change in fair value of warrant liability | 241,000 | 800,000 | 5 | −119,000 | — | |
| Gain on settlement of vendor payable | 998,000 | — | — | — | — | |
| Other | 156,000 | — | 20,000 | — | −38,000 | |
| Total Other Income (Expense), Net | −16 | 1 | 6 | −373,000 | 498,000 | |
| Net Loss | −28 | −13 | −8 | −21 | −58 | |
| Dividend on Series L Preferred Stock | −320,000 | — | — | — | — | |
| Deemed dividend | −6 | — | — | — | — | |
| Net Loss attributable to common stockholders | −34 | −13 | — | — | — | |
| Net Loss Per Share - Basic | −6.68 | −6.94 | −5.64 | −19.66 | −2.06 | |
| Net Loss Per Share - Diluted | −6.68 | −6.94 | −5.64 | −19.66 | — | |
| Weighted average common shares outstanding - basic | 6 | 2 | 1 | 1 | 28 | |
| Weighted average common shares outstanding - diluted | 6 | 2 | 1 | 1 | — |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2025 2025-09-30 | FY 2025 2025-06-30 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 7 | — | — | 4 | 1 | |
| Restricted cash | 94,000 | — | — | 93,000 | — | |
| Deferred offering costs | 634,000 | — | — | — | — | |
| Prepaid expenses and other current assets | 567,000 | — | — | 188,000 | 84,000 | |
| Total Current Assets | 8 | — | — | 4 | 14 | |
| TOTAL ASSETS | 8 | 4 | 7 | 4 | 14 | |
| Accounts payable | 748,000 | — | — | 4 | 4 | |
| Accrued expenses | 2 | — | — | 2 | 1 | |
| Warrant liability | 11,000 | — | — | 252,000 | 1 | |
| Total Current Liabilities | 2 | — | — | 6 | 7 | |
| Preferred stock value | — | 1,000 | 1,000 | 1,000 | 1,000 | |
| Common stock, par value $0.001, 250,000,000 shares authorized, 25,534,173 and 2,234,328 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 26,000 | 3,000 | 3,000 | 2,000 | 1,000 | |
| Additional paid in capital | 730 | 721 | 700 | 694 | 690 | |
| Accumulated deficit | −724 | −718 | −726 | −695 | −682 | |
| Total Stockholders Equity (Deficit) | 6 | 3 | −26 | −2 | 7 | |
| TOTAL LIABILITIES AND STOCKHOLDERS EQUITY (DEFICIT) | 8 | 4 | 7 | 4 | 14 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Stock based compensation | 432,000 | 230,000 | — | — | — | |
| Change in fair value of Greenshoe Rights liability | −11 | — | — | — | — | |
| Issuance of warrants for VRT waiver | 44,000 | — | — | — | — | |
| Gain on extinguishment of debt | −200,000 | — | — | −31,000 | — | |
| (Increase) Decrease in prepaid expenses and deferred offering costs | 377,000 | −104,000 | −21,000 | — | 174,000 | |
| Decrease in operating lease right-of-use assets | — | 53,000 | — | — | — | |
| Increase (Decrease) in accounts payable and accrued expenses | −1 | 937,000 | 2 | −2 | 7 | |
| (Decrease) in operating lease liability | — | −58,000 | −116,000 | −86,000 | — | |
| Net Cash Used in Operating Activities | −13 | −13 | −9 | −15 | −16 | |
| Sale of short-term investments | — | 13 | −2 | 12 | −23 | |
| Net Cash Provided by Investing Activities | — | 13 | −2 | 12 | −23 | |
| Exercise of warrants and issuance of inducement warrants for cash, net | 5 | — | — | — | 16 | |
| Proceeds from issuance of common stock and warrants, net | — | 3 | 6 | — | — | |
| Proceeds from issuance of Series L Preferred Stock and warrants, net | 11 | — | — | — | — | |
| Payment of dividend on Series L Preferred Stock | −229,000 | — | — | — | — | |
| Net Cash Provided by Financing Activities | 16 | 3 | 6 | −224,000 | 42 | |
| Net Increase in Cash and Cash Equivalents and Restricted Cash | 3 | 3 | −5 | −3 | 4 | |
| Interest | — | — | — | — | — | |
| Income taxes | — | — | — | — | — | |
| Fair value of prefunded warrants issued for Committed Equity Facility fee | 672,000 | — | — | — | — | |
| Fair value of common stock and warrants issued for services | 718,000 | — | 702,000 | — | 39 | |
| Fair value of prefunded warrant and common stock to settle vendor payable | 847,000 | 810,000 | — | — | — | |
| Fair value of common stock issued for dividends | 91,000 | — | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is GT Biopharma, Inc.'s CIK number?
GT Biopharma, Inc.'s SEC CIK number is 0000109657 (109657). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find GT Biopharma, Inc.'s SEC filings?
All of GT Biopharma, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did GT Biopharma, Inc. last report earnings?
GT Biopharma, Inc. (GTBP) most recently filed an earnings 8-K with the SEC on Nov 14, 2025, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001493152-25-022631). This is GT Biopharma, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is GT Biopharma, Inc.'s most recent earnings 8-K?
GT Biopharma, Inc.'s latest earnings 8-K (Item 2.02) was filed Nov 14, 2025 under accession 0001493152-25-022631. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View GT Biopharma, Inc.'s latest earnings 8-K →
Look up any company's CIK number →